Literature DB >> 17089154

Value of basal serum cortisol to detect corticosteroid-induced adrenal insufficiency in elite cyclists.

M Guinot1, M Duclos, N Idres, J C Souberbielle, A Megret, Yves Le Bouc.   

Abstract

The frequent use of glucocorticoids by athletes necessitates testing for adrenal insufficiency because of the risk of death in cases of associated severe stress (trauma, infection). During the 2001 and 2002 sporting seasons, we assessed the value of measuring baseline serum cortisol concentrations and the frequency of corticosteroid use during compulsory medical tests carried out by the French Cycling Federation on 659 elite cyclists (585 men and 74 women); the risk of adrenal insufficiency is negatively correlated with the basal serum cortisol level. Adrenal insufficiency was suspected in 34 cyclists (5.2%; 22 in 2001 and 12 in 2002) on the basis of below normal cortisol concentrations and in three cyclists (in 2001) because they had received corticosteroid treatment. In 2001, 10 of the 25 cyclists convoked underwent baseline follow-up serum cortisol determinations and 15 underwent dynamic exploration of adrenal function with the short ACTH test. Adrenal function was found to be deficient in four of these cyclists, at the limits of the normal range in four and normal in seven. Based on these results, the FFC sent a questionnaire in 2002 to all the cyclists to assess the use of corticosteroid in this population. This survey revealed that 85 of 538 cyclists (15.8%) had received corticosteroid treatment in the previous 3 months. Moreover, 11 of the 12 cyclists (92%) with low basal serum cortisol concentrations had received corticosteroid therapy. These results show that basal serum cortisol is relevant to detect adrenal insufficiency in sportsmen, in particular in cases of values below the normal range. The high frequency of corticosteroid use among elite cyclists, and in particular road cyclists who are at risk of trauma and infection, justifies screening tests to detect adrenal insufficiency.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 17089154     DOI: 10.1007/s00421-006-0332-4

Source DB:  PubMed          Journal:  Eur J Appl Physiol        ISSN: 1439-6319            Impact factor:   3.078


  32 in total

1.  Comparison of low and high dose corticotropin stimulation tests in patients with pituitary disease.

Authors:  J Mayenknecht; S Diederich; V Bähr; U Plöckinger; W Oelkers
Journal:  J Clin Endocrinol Metab       Date:  1998-05       Impact factor: 5.958

2.  Increased cortisol production in women runners.

Authors:  A L Villanueva; C Schlosser; B Hopper; J H Liu; D I Hoffman; R W Rebar
Journal:  J Clin Endocrinol Metab       Date:  1986-07       Impact factor: 5.958

3.  The systemic effects of intra-articular corticosteroid.

Authors:  B E Koehler; M B Urowitz; D W Killinger
Journal:  J Rheumatol       Date:  1974-03       Impact factor: 4.666

4.  Increased body iron stores in elite road cyclists.

Authors:  Yves Deugnier; Olivier Loréal; François Carré; Andŕe Duvallet; Fabien Zoulim; Jean Pierre Vinel; Jean Claude Paris; Denis Blaison; Romain Moirand; Bruno Turlin; Yves Gandon; Véronique David; André Mégret; Michel Guinot
Journal:  Med Sci Sports Exerc       Date:  2002-05       Impact factor: 5.411

5.  Dose response with fluticasone propionate on adrenocortical activity and recovery of basal and stimulated responses after stopping treatment.

Authors:  A M Wilson; E J Sims; B J Lipworth
Journal:  Clin Endocrinol (Oxf)       Date:  1999-03       Impact factor: 3.478

6.  Hypothalamic dysfunction in overtrained athletes.

Authors:  J L Barron; T D Noakes; W Levy; C Smith; R P Millar
Journal:  J Clin Endocrinol Metab       Date:  1985-04       Impact factor: 5.958

7.  Optimizing the diagnostic criteria for standard (250-microg) and low dose (1-microg) adrenocorticotropin tests in the assessment of adrenal function.

Authors:  M Zarković; J Cirić; M Stojanović; Z Penezić; B Trbojević; M Drezgić; M Nesovic
Journal:  J Clin Endocrinol Metab       Date:  1999-09       Impact factor: 5.958

8.  Low-dose adrenocorticotropin test reveals impaired adrenal function in patients taking inhaled corticosteroids.

Authors:  J Broide; R Soferman; S Kivity; A Golander; G Dickstein; Z Spirer; Y Weisman
Journal:  J Clin Endocrinol Metab       Date:  1995-04       Impact factor: 5.958

9.  Evaluation of the integrity of the hypothalamic-pituitary-adrenal axis by insulin hypoglycemia test.

Authors:  E Erturk; C A Jaffe; A L Barkan
Journal:  J Clin Endocrinol Metab       Date:  1998-07       Impact factor: 5.958

10.  The one microgram adrenocorticotropin test in the assessment of hypothalamic-pituitary-adrenal function.

Authors:  B Ambrosi; L Barbetta; T Re; E Passini; G Faglia
Journal:  Eur J Endocrinol       Date:  1998-12       Impact factor: 6.664

View more
  2 in total

1.  Assessing recovery of adrenal function in glucocorticoid-treated patients: Our strategy for screening and management.

Authors:  Najat Draoui; Achwak Alla; Nada Derkaoui; Nisrine Bouichrat; Aymane Loukili; Siham Rouf; Hanane Latrech
Journal:  Ann Med Surg (Lond)       Date:  2022-05-07

2.  Metabolomic signatures in elite cyclists: differential characterization of a seeming normal endocrine status regarding three serum hormones.

Authors:  Boris Labrador; François-Xavier Lejeune; Alain Paris; Cécile Canlet; Jérôme Molina; Michel Guinot; Armand Mégret; Michel Rieu; Jean-Christophe Thalabard; Yves Le Bouc
Journal:  Metabolomics       Date:  2021-07-06       Impact factor: 4.290

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.